Castle Biosciences, Inc. (CSTL) vs Nuvalent Inc (NUVL)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| CSTL | NUVL | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Diagnostics & Research | Biotechnology |
| Size band | SMALL | MID |
| Listing | Nasdaq GM | Nasdaq GM |
| Country | United States | United States |
| Theme | diagnostics | oncology |
| Price and returns | ||
| Last close | $33.30 | $123.96 |
| Return · 1 week | +3.53% | 0.00% |
| Return · 1 month | −7.32% | 0.00% |
| Return · 3 months | +39.39% | 0.00% |
| Return · year to date | −13.60% | +22.93% |
| Return · 1 year | +38.98% | +26.87% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −24.80% | −0.02% |
| 52-week high | $44.28 | $123.99 |
| 52-week low | $17.72 | $87.30 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $1.01B | $9.79B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $11.99M | $149.69M |
| Employees | 1,002 | 234 |
| Valuation | ||
| Price to earnings · trailing | n/a (negative earnings) | n/a (negative earnings) |
| Price to earnings · forward | n/a (negative forward earnings) | n/a (negative forward earnings) |
| Price to sales | 2.83× | — |
| Price to book | 2.15× | 8.33× |
| Enterprise value to EBITDA | n/a (negative EBITDA) | — |
| Enterprise value to revenue | 2.18× | — |
| Earnings per share · trailing | -0.64 | -6.06 |
| Profitability | ||
| Gross margin | 77.26% | — |
| Operating margin | −2.96% | 0.00% |
| Profit margin | −5.43% | — |
| Return on equity | −4.20% | −41.19% |
| Return on assets | −1.36% | −22.51% |
| Growth | ||
| Revenue growth | +20.10% | — |
| Balance sheet and payout | ||
| Debt / equity (%) | 7.80 | — |
| Current ratio | 6.04 | 16.14 |
| Dividend yield | 0.00% | — |
| Payout ratio | 0.00% | 0.00% |
| Trend and volatility | ||
| RSI · 14 | 48.64 | — |
| ADX · 14 | 15.19 | — |
| 50-day average | $33.76 | — |
| 200-day average | $28.59 | — |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 4.23% | — |
The full CSTL analysis
Everything this table leaves out for Castle Biosciences, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the CSTL argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full CSTL analysisThe full NUVL analysis
Everything this table leaves out for Nuvalent Inc: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the NUVL argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full NUVL analysis